VKTX Stock Edges Higher In August Ahead Of Early-Stage Obesity-Drug Data Release In Q3
Investors are now awaiting results from an early-stage study of VK2735 testing different ways to keep weight off after an initial course of treatment.
Stocktwits
More News
Can CagriSema Help Novo Nordisk Close the Gap With LLY in Obesity?
NVO's CagriSema is under U.S. regulatory review for obesity, with continued clinical progression to expand use amid increasing competition from LLY.
Zacks
Viking Therapeutics Stock Is Down 66% From Its Peak. Here's What Comes Next.
Key PointsVK2735 is Viking's lead candidate for obesity with dual-formulation potential...
Nasdaq News: Markets
Why Is Viking Therapeutics (VKTX) Up 2.3% Since Last Earnings Report?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough?
Key PointsViking's strong cash position funds operations through major milestones in 2027 and 2028...
Nasdaq News: Markets
Can Awiqli Help Novo Nordisk Build a New Growth Engine Beyond GLP-1s?
NVO's U.S. launch of Awiqli introduces the first once-weekly basal insulin, potentially giving the company a new growth opportunity beyond its pressured GLP-1 franchise.
Zacks
How Does LLY's Q2 GLP-1 Portfolio Performance Stack Up Against NVO's?
Eli Lilly's GLP-1 portfolio outpaces its rival in Q2, while Foundayo gains momentum and can challenge Wegovy's early oral obesity lead.
Zacks
LLY Up Around 6% Post Robust Q2 Results: Buy, Sell or Hold the Stock?
Lilly's strong Q2, GLP-1 momentum and broad pipeline support growth, but valuation and rising competition remain key risks.
Zacks
Can Novo Nordisk's GLP-1 Pill Momentum Offset LLY's Growing Edge?
NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.
Zacks
LLY's Foundayo Posts $98M in Q2 Sales: What's Next for the Oral GLP-1?
Lilly's Foundayo records $98M in Q2 sales, while rising prescriptions, broader access and global expansion set the stage for H2 growth